Renerve (ASX: RNV) said that a recent comparative study showed that patients undergoing peripheral nerve surgery who used its NervAlign nerve cuff saw a major decrease in post-surgery pain compared to patients who did not use the nerve cuff, according to a Friday Australian bourse filing.
Patients who were treated with the nerve cuff were more likely to indicate they would have their procedure again.
The nerve cuff is designed to protect repaired and regenerating nerves during the healing process after peripheral nerve injuries or repair surgery, per the filing.
Its shares surged over 31% on market close on Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.